Source:http://linkedlifedata.com/resource/pubmed/id/20142415
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2010-5-31
|
pubmed:abstractText |
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis and limited response to platinum-based chemotherapy. Several lines of evidence support a role for the anti-apoptotic protein Bcl-x(L) in MPM chemoresistance. Since it has been recently suggested that Mcl-1 cooperates with Bcl-x(L) for protection against cell death, we investigated the response of mesothelioma cell lines to the downregulation of Bcl-x(L) (alone or in combination with cisplatin) and the potential interest of its concomitant inhibition with that of Mcl-1. Using RNA interference, we showed that Bcl-x(L) depletion sensitized two highly chemoresistant mesothelioma cell lines to cisplatin and that under this treatment, one cell line, MSTO-211H, displayed an apoptotic type of cell death, whereas the other, NCI-H28, evidenced mainly necrotic-type cell death. Otherwise, the inhibition of Mcl-1 by cisplatin may contribute to this induction of cell death observed after Bcl-x(L) downregulation. Strikingly, we observed that the simultaneous inhibition of Bcl-x(L) and Mcl-1 using small interfering RNA (siRNA) induced a massive cell death in the absence of chemotherapy and was sufficient to avoid escape to treatment in MSTO-211H cells. In NCI-H28, the addition of a low cisplatin concentration allowed to impede the long-term recovery observed after treatment by the siRNA combination. Together, these findings provide a strong molecular basis for the clinical evaluation of therapies targeting both Bcl-x(L) and Mcl-1, alone or in combination with conventional chemotherapy, for the treatment of MPM.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/bcl-X Protein,
http://linkedlifedata.com/resource/pubmed/chemical/myeloid cell leukemia sequence 1...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1460-2180
|
pubmed:author |
pubmed-author:AbeilardEdwigeE,
pubmed-author:BrotinEmilieE,
pubmed-author:DenoyelleChristopheC,
pubmed-author:GauduchonPascalP,
pubmed-author:GiffardFlorenceF,
pubmed-author:GouxDidierD,
pubmed-author:IcardPhilippeP,
pubmed-author:Meryet-FiguièreMatthieuM,
pubmed-author:PoulainLaurentL,
pubmed-author:VarinEmilieE
|
pubmed:issnType |
Electronic
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
984-93
|
pubmed:meshHeading |
pubmed-meshheading:20142415-Antineoplastic Agents,
pubmed-meshheading:20142415-Apoptosis,
pubmed-meshheading:20142415-Blotting, Western,
pubmed-meshheading:20142415-Cell Line, Tumor,
pubmed-meshheading:20142415-Cisplatin,
pubmed-meshheading:20142415-Down-Regulation,
pubmed-meshheading:20142415-Humans,
pubmed-meshheading:20142415-Mesothelioma,
pubmed-meshheading:20142415-Microscopy, Electron, Transmission,
pubmed-meshheading:20142415-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:20142415-bcl-X Protein
|
pubmed:year |
2010
|
pubmed:articleTitle |
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
|
pubmed:affiliation |
Unité BioTICLA (Biologie et Thérapies Innovantes des Cancers Localement Agressifs) du Groupe Régional d'Etudes sur le Cancer (EA 1772, Université de Caen Basse-Normandie et IFR146 ICORE), Centre de Lutte Contre le Cancer François Baclesse, Avenue du Général Harris, BP5026, 14076 Caen Cedex 05, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|